Angiosarcomatous transdifferentiation of metastatic melanoma

J Cutan Pathol. 2020 Dec;47(12):1211-1214. doi: 10.1111/cup.13857. Epub 2020 Sep 28.

Abstract

Melanoma is known to show considerable variation in its histopathological presentation. In exceptional cases, heterologous or divergent differentiation (metaplastic melanoma) can be observed. We report a case of a 69-year-old man who was diagnosed with nodular melanoma on the right upper leg. One year later, the patient presented with an inguinal lymph node metastasis and a lymph node dissection was carried out. In two out of five positive lymph nodes, an angiosarcomatous component was found next to a conventional melanoma component. Shortly after, the patient developed two in-transit metastases in which again an angiosarcomatous component was seen. The vascular component stained positive for ERG and CD31 and negative for melanocytic markers (Mart-1, S100, SOX-10), while the conventional melanoma had an opposite staining pattern. Molecular analysis on both components showed an identical mutation in the NRAS gene, which in our opinion proves the divergent differentiation. To the best of our knowledge, this is the first case report describing angiosarcomatous transdifferentiation of melanoma.

Keywords: angiosarcoma; angiosarcomatous transdifferentiation; divergent differentiation; heterologous differentiation; melanoma; transdifferentiation.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Cell Transdifferentiation / genetics
  • GTP Phosphohydrolases / genetics
  • Hemangiosarcoma / blood supply
  • Hemangiosarcoma / drug therapy*
  • Hemangiosarcoma / metabolism
  • Hemangiosarcoma / pathology*
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunohistochemistry
  • Inguinal Canal / pathology*
  • Lymph Node Excision / methods
  • Lymphatic Metastasis / diagnosis*
  • Male
  • Melanoma / secondary*
  • Melanoma, Cutaneous Malignant
  • Membrane Proteins / genetics
  • Mutation
  • Nivolumab / therapeutic use
  • Palliative Care
  • Platelet Endothelial Cell Adhesion Molecule-1 / metabolism
  • Skin Neoplasms / secondary*
  • Transcriptional Regulator ERG / metabolism
  • Treatment Outcome

Substances

  • ERG protein, human
  • Immune Checkpoint Inhibitors
  • Membrane Proteins
  • PECAM1 protein, human
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Transcriptional Regulator ERG
  • Nivolumab
  • GTP Phosphohydrolases
  • NRAS protein, human